Back to search results

Study of AGN-151607-DP for Ventral Hernia Repair

This study is testing an investigational drug called AGN-151607-DP for adults undergoing open surgery to fix a ventral hernia. A ventral hernia happens when belly muscles weaken, allowing organs to push through, causing a bulge. The study aims to see if AGN-151607-DP can help close the belly wall safely and effectively after surgery, potentially avoiding a more complex procedure. You would be randomly assigned to receive either AGN-151607-DP or a placebo (an inactive substance) through an injection. Researchers will monitor for any side effects (adverse events) and how well the hernia is repaired. The study is looking for about 200 participants aged 18 to 80 who have a midline ventral hernia needing open surgery. The current recruitment status is unclear.

Study design
This is an interventional study planning to enroll 200 participants. Participants will be randomly assigned to receive either the study drug or a placebo.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for adverse events for up to approximately 25 months after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07226791

Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants Undergoing Open Abdominal Ventral Hernia Repair

Recruiting
PHASE2Ages 18–80InterventionalTreatment
AbbVie
~200 participants
Updated 2026-08-25 on ClinicalTrials.gov
What's tested:AGN-151607-DPPlacebo for AGN-151607-DP

At a glance

Recruiting sites
11 of 13 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Percentage of Participants Achieving Primary Fascial Closure (PFC) Without Use of Component Separation Technique (CST) in Open Ventral Hernia Surgical Repair
Measured over Up to approximately 1 Month
+1 more outcome measured

Conditions

Ventral Hernia

Explore related trials

Ventral Hernia

Where it's being run

13 sites across 11 states
Florida3
California1
Illinois1
Kansas1
Minnesota1
North Carolina1
Ohio1
Pennsylvania1

Study leadership

  • ABBVIE INC. · STUDY_DIRECTOR · AbbVie

Who to contact

ABBVIE CALL CENTER
[email protected]
844-663-3742
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Exclusion

Medical condition that may put the participant at increased risk with exposure to AGN-151607-DP, including diagnosed muscular dystrophy (e.g., Duchenne's muscular dystrophy), myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, mitochondrial disease, or any other significant disease which might interfere with neuromuscular function.
History of abdominal or hernia repair surgery requiring hospitalization within 6 months prior to screening.

What this trial measures

  • Percentage of Participants Achieving Primary Fascial Closure (PFC) Without Use of Component Separation Technique (CST) in Open Ventral Hernia Surgical RepairUp to approximately 1 Month

    PFC will be defined as the ability to achieve fascia to fascia midline approximation.

  • Percentage of Participants Experiencing Adverse EventsUp to approximately 25 Months

    An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.